Regional overviews

celebrating 20 years Middle East & North Africa

STATISTICS  
Number of products launched: 8 (2017: 2)#
IMS value of pipeline as at 30 June 2018 anticipated to be launched in:  
0 – 2 years USD160 million
3 – 5 years USD3 million
Number of product recalls: 0 (2017: 0)
Average staff turnover: 10,9% (2017: 18,2%)
Number of work-related fatalities: 0 (2017: Nil)
Number of permanent employees:  
Number of permanent employees:  

# The number of product launches has been restated as a result of the refinement of the product launch definition.

 

We supply globally branded pharmaceutical products as well as local brands into multiple territories within Middle East and North Africa ("MENA"). Egypt, Algeria and Saudi Arabia combined contributed approximately 50% to total sales in MENA for the 2018 financial year.

KEY COUNTRIES

Algeria, Egypt, Morocco, Saudi Arabia, United Arab Emirates

Contribution to Group revenue

Revenue - R'million 2018 2017 (CER) % change
Regional Brands 369 413 (11)
Anaesthetics 156 228 (32)
Thrombosis 159 166 (4)
High Potency & Cytotoxics 193 242 (20)
Total 877 1 049 (16)
 
  • The MENA pharmaceutical sector was valued at USD26,0 billion as at 30 June 2018.
  • The top nine major markets (which include, inter alia, the Kingdom of Saudi Arabia, Algeria, Egypt and the United Arab Emirates) were value at USD17,4 billion and grew 9,3%.
Source: June 2018 IMS